×
There are updates to the co-pay card. If your patient is having issues using their co-pay card, click here for more information.
Otezla® (apremilast) Copay and Patient Support
Close window icon

3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease. Read less

Read less

First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA

First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA

SEE THE DATA REFERENCES

No lab monitoring. No TB or baseline blood panel tests. No planning around live vaccines 1 START TODAY WITHOUT DELAY

No lab monitoring. No TB or baseline blood panel tests. No planning around live vaccines 1

START TODAY WITHOUT DELAY REFERENCES

A small pill with a big history: 920,000+ patients treated globally since 2014 1.2,* PsO SAFETY PsA SAFETY

A small pill with a big history: 920,000+ patients treated globally since 2014 1.2,*

PsO SAFETY PsA SAFETY REFERENCES & FOOTNOTE

Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=57% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.

FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.

References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.

CO-PAY AND PATIENT SUPPORT

Support services are available for Otezla patients—Don’t wait to get your patients started

ENROLLING IN THE $0 CO-PAY CARD * PROGRAM MAY HELP ELIGIBLE COMMERCIALLY INSURED PATIENTS START THEIR OTEZLA PRESCRIPTION WITHOUT DELAY

Otezla $0 Co-Pay Card

OTEZLA $0 CO-PAY CARD

Patients enrolled in the Co-Pay Card Program WERE 2x more likely to fill their prescription compared to those who do not enroll 1,†

Based on new commercially insured patients who received an Otezla prescription June 1, 2022 - May 31, 2023.

*Eligibility criteria and program maximums apply. Click here for full Terms and Conditions.

3 SIMPLE WAYS FOR PATIENTS TO ENROLL IN THE CO-PAY PROGRAM:

Graphic of a QR code

Scan the QR code

ENCOURAGE COMMERCIALLY INSURED PATIENTS TO ENROLL IN
THE $0 CO-PAY CARD PROGRAM FOR OTEZLA BEFORE LEAVING THE OFFICE

WE ARE COMMITTED TO HELPING YOUR PATIENTS ACCESS OTEZLA AT LOW COST

  • If your patients are uninsured or underinsured, Amgen® Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen® that helps qualifying patients access Amgen medicines at no cost. Click here to learn more.
  • Amgen® SupportPlus Specialists help your Medicare patients understand their current insurance plan and anticipated out-of-pocket costs for Otezla. For patients who want to switch Medicare plans, we can help identify other local options. We may also be able to refer eligible patients for Medicare Extra Help (Low Income Subsidy) or put them in touch with independent nonprofit foundations.

Support provided through independent nonprofit foundations and not through Amgen® SupportPlus. Amgen® SupportPlus has no control over independent, third-party programs and provides referrals as a courtesy only.

AMGEN® NURSE PARTNERS

Dedicated Amgen® Nurse Partners will be with your patients along the way to offer supplemental support and provide information about resources to help them access their prescribed Amgen medication.

Amgen® Nurse Partners can provide supplemental support, including:

  • Guidance on resources that may help lower out-of-pocket medication costs
  • Assistance to help your patients stay on track with their medication
  • Answers to your questions about Amgen® SupportPlus

Your Otezla patients can enroll in the Amgen Nurse Partner Program online at https://www.otezla.com/enroll or by calling 1-844-4OTEZLA (1-844-468-3952).

Amgen® Nurse Partners are only available to patients who are prescribed certain Amgen products. They are not part of your treatment team and do not provide medical advice, nursing, or case management services. Amgen® Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Amgen® Nurse Partner

GET CONNECTED WITH A DEDICATED AMGEN® NURSE PARTNER BY CALLING

1-844-4OTEZLA

(1-844-468-3952)

8AM-8PM ET, MONDAY-FRIDAY

Accordion icon

IMPORTANT SAFETY INFORMATION 

Contraindications

Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation 

Warnings and Precautions

Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy

IMPORTANT SAFETY INFORMATION

Contraindications

  • Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
  • Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
  • Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
    • Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
    • Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
    • Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
  • Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider
    discontinuation of Otezla
    • Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
    • Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
    • Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of
      patients taking placebo
  • Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

  • Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
  • Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
  • Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

  • Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss

Please click here for the full Prescribing Information.

INDICATIONS

Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Reference: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.